We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

ROCHE DIAGNOSTICS CORP

Roche Diagnostics Corporation is the North American headquarters of Roche Diagnostics, a global leader in diagnostics... read more Featured Products: More products

Download Mobile App




Automated Extraction of FFPE Tissue for High-Risk HPV Testing

By LabMedica International staff writers
Posted on 07 Jul 2016
The testing for high-risk human papillomavirus (HR-HPV) in head and neck squamous cell carcinomas is important for both prognostication and clinical management. Several testing platforms are available for HR-HPV; however, effective alternative automated approaches are needed.

High-risk human papillomavirus (HR-HPV) is now a well-established etiologic agent in a subset of head and neck squamous cell carcinomas (HNSCCs) that has an incidence on the rise, particularly with respect to oropharyngeal squamous cell carcinoma (OPSCC), which demonstrates an association with transcriptionally active virus in up to 80% of tumors.

Pathologists from Massachusetts General Hospital (Boston, MA, USA) collected from 62 archival specimens of formalin-fixed, paraffin-embedded (FFPE) samples of HNSCC. Overall OPSCC represented slightly more than half (55%) of the HNSCCs tested. These were prepared using the automated system by deparaffinization and dehydration followed by tissue lysis. Corresponding FFPE samples were evaluated for HR-HPV by in situ hybridization (ISH) and p16 by immunohistochemistry. Discrepant cases were adjudicated by polymerase chain reaction (PCR).

The scientists used the automated Roche cobas 4800 System Platform (Roche Diagnostics, Risch-Rotkreuz, Switzerland), which consists of an automated instrument for sample preparation and DNA extraction followed by and coupled to a thermocycler and analyzer for performance of real-time PCR and subsequent detection of target DNA sequences. Immunohistochemical expression of p16 was evaluated by deparaffinizing 5µm FFPE sections of HNSCCs and performing antigen retrieval using the Leica Bond protocol (Leica Biosystems, Buffalo Grove, IL, USA).

The investigators found 32/62 (52%) of formalin-fixed, paraffin-embedded tumors were positive for HR-HPV by cobas. There were 28/32 (88%) of cases were the HPV 16 subtype and 12% (4 /32) were other HR-HPV subtypes. Corresponding testing with ISH was concordant in 92% (57 /62). Compared with the adjudication PCR standard, there were three false-positive cases by cobas. For the OPSCC, cobas had positive and negative predictive values of 100%, whereas for non-OPSCC, the positive predictive value was 57% and the negative predictive value was 100%.

The authors concluded that concordance in HNSCC HR-HPV status between cobas and ISH was more than 90%. The cobas demonstrated a sensitivity of 100% and a specificity of 91% for detection of HR-HPV. They said the advantages favoring cobas included its automation, cost efficiency, objective results, and ease of performance. The study was published in an early online edition of the journal Archives of Pathology & Laboratory Medicine.

Related Links:
Massachusetts General Hospital
Roche Diagnostics
Leica Biosystems

New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA
New
Piezoelectric Micropump
Disc Pump
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.